Overview

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Status:
Completed

Trial end date:
2010-11-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI)following single dose administration of FF/VI via the novel dry powder inhaler in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone
Xhance